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Summary  
 
Cumulatively, breast, cervical, ovarian and uterine cancer account for more than 50% of cancers in 
women in India. Distinct differences in phenotype (clinical presentation) suggest underlying 
differences in cancer biology and genetics - the peak age of onset of breast and ovarian cancer 
appears to be a decade earlier in India (45- 50yrs) than developed nations (> 60 years). 
Understanding these differences through research to derive India-specific paradigms for diagnosis, 
screening, prevention and treatment is critical and essential to improving women's 
health in India. Since the sequencing of the human genome in 2001, applications of advancing 
technologies such as massively parallel sequencing have transformed our understanding of the 
genetic and environmental drivers of cancer. The $1000 dollar whole genome sequence is now a 
reality. How can these technologies be best harnessed to provide health care solutions at 
scale and at budget for a country of 1.2 billion people? What research programs are necessary to 
answer India specific questions and build capacity for innovative solutions using these 
technologies? We performed a systematic review and convened a workshop with key stakeholders 
to address these issues. We highlight challenges, ongoing genomics research, developments in 
infrastructure and suggests key priorities for research.  
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Introduction  
Women’s cancer (breast, cervical, ovarian and uterine cancers) cause in excess of 1 million deaths 
each year worldwide; about three times more deaths each year than maternal mortality. 1 The 
majority of these cancer deaths will occur in Low and middle income countries. 1 India’s cancer 
burden, currently estimated at over 1.5 million new cases  is predicted to nearly double in the next 
20 years , with age-adjusted mortality rates of 64.5 per 100,000 (GLOBOCAN 2012).2  3The burden 
among Indian women is higher than men, in marked contrast with the worldwide picture of cancer 
in which the overall age standardized cancer incidence rate is almost 25% higher in men than in 
women.4 Cumulatively, breast, cervical, ovarian and uterine cancer account for more than 50% of 
cancers in women in India. (Figure 1) 
  
Whilst cancer incidence rates are relatively low in India, cancer mortality rate is very high, at 68% 
of the annual incidence. This ratio indicates that fewer than 30% of Indian patients with cancer 
survive 5 years or longer after diagnosis.5 In view of the limitations in the available data, (including 
low coverage, particularly in rural areas), the true proportion could be significantly lower. By 
contrast, in North America and Western Europe, overall 5 year survival for all cancers is about 
60%. Delayed diagnosis and inadequate, incorrect or suboptimum treatment (including patient 
inability to access or complete appropriate therapies) are significant causes of poor cancer survival 
in India.6 7 Hitherto unidentified differences in tumour biology may also contribute to poorer 
survival. The delivery of affordable and equitable cancer care is thus one of India’s greatest public 
health challenges.8  
 
Since the sequencing of the human genome in 2001,9 10 applications of advancing technologies such 
as massively parallel sequencing have transformed our understanding of the genetic and 
environmental drivers of cancer. 11-13The under $1000 dollar whole genome sequence is now a 
reality. Insightful applications of this technology have the potential to transform health by delivery 
of ‘precision medicine’ or ‘individualized medicine’. How can these technologies be best harnessed 
to provide health care solutions at scale and at budget for a country of 1.2 billion people that has 
huge diversity and a fragmented healthcare system? What research programs are necessary to 
answer India specific questions and build capacity for innovative solutions using these 
technologies?  
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Search strategy and Selection criteria  
We performed a systematic search of published literature in English using the terms ‘India’, 
‘cancer’, ‘genomics’, ‘Genome-wide association studies’ ( GWAS), search date any published to 
December 2016. We searched Pubmed and Google. Papers were selected for inclusion if they were 
reviews or original research with data relevant to the application of genomics in women’s cancer 
(breast/cervical/ovarian/uterine) in India. We convened a workshop drawing together stakeholders 
from the World Health Organization, India’s National Institute of Cancer Prevention and Research, 
United States National Cancer Institute, Department of Biotechnology, India, Chandigarh Research 
Innovation Cluster, Postgraduate Institute of Medical Education and Research, National Institute of 
Biomedical Genomics, Public Health Foundation of India, Research Councils UK, British Council, 
Wellcome Trust India alliance, and Illumina. 
 
Challenges from women’s cancer in India  
Changing demographics in India including rapid economic growth, increasing life expectancy, 
declining mortality from communicable diseases and changes in lifestyle are mirrored by a change 
in cancer profiles. 14 Breast cancer is now the most common cancer diagnosed in women with an 
Age standardized rate (ASR) of 25/100,000 and 27% of cancers in women, followed by cervical 
cancer, ASR of 22/100,000 and 22.9% of cancers diagnosed in women. 15 However, there is 
variation within the country, with cervical cancer still being the leading cause of cancer in many 
rural registries as demonstrated in the National cancer registry programme. 2 Ovarian cancer is the 
4th most common cancer accounting for 5%, ASR of 4.9/100,000. 3  
 
India’s National Cancer Control Programme was launched in 1976, and has been incorporated as 
part of the National Program for the Prevention of Cancer, Diabetes, Cardiovascular Disease and 
Stroke (NPCDS) since 2010. Large scale implementation of cancer prevention and control 
strategies has yet to take place, and public expenditures on cancer remain low at 1.2% of GDP.8 
Currently, there is no national organized screening program in India. However the NPCDS has 
introduced opportunistic screening for breast and cervical cancers alongside screening for Diabetes 
and Hypertension in a 100 selected districts in 21 states. 16 The Ministry of Health & Family 
Welfare, Government of India has recently launched the operational guidelines for screening and 
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prevention of three common cancers oral, breast and cervical cancer.17 There are also substantial 
variations in health systems, access and coverage between the various states in India.  
Rationale for cancer genomics research in India - differences in cancer biology and 
epidemiology 
Significant clinical differences in cancer behaviour demonstrate that data derived in the West 
cannot be applied without modification to India. For instance, oral cancer occurs more frequently in 
Indian populations; nearly 73.4% of Head and neck cancer in India is from gingivobuccal origin as 
compared to 22% of cancer in the West and is associated with extensive tobacco and betel nut 
chewing practices. 18 For breast and ovarian cancers, the peak age of onset in Asian countries 
appears to be a decade younger (45-50 years) than the peak age in the west (> 60). 19 By contrast 
almost half of all breast and ovarian cancers in the UK will be diagnosed in women over the age of 
65 years. 20 These epidemiological differences may be underpinned by a difference in biology – 
incidence of triple negative breast cancer has been reported as higher in India. 19 21 Multicenter large 
scale studies with standardized histopathology are needed to confirm these observations (Box1) 
 
These findings have social and economic ramifications but also practical implications for diagnosis 
and management. For instance, the accuracy of mammography in Indian women as a screening tool 
may be lower due to differences in breast architecture in younger women. A key deficit previously 
highlighted is the lack of cancer research to guide early detection, prevention, and treatment 
strategies tailored to India rather than international guidelines suited to implementation in high 
income countries. 22
 
 
Significant regional differences also exist within India with variations in cancer type and 
distribution between the different Indian states.     Total cancer rates in population-based registries 
vary by more than 6-fold across the country , and more than 30-fold differences for sites such as the 
oesophagus (East Khasi Hills, North East India at 71.2 per 100,000 males versus Barshi, Western 
India at 2.7 per 100,000 males).2 For women, a comparison of incidence rates for Breast cancer 
shows a 10-fold variation between the highest, Delhi at Age adjusted rate (AAR) of 41 to 
Naharlagun (excluding Papumpare) in the North-East of India at AAR 4.4. ( Figure 2) 2 For 
Cervical cancer, a fivefold difference is seen with the highest incidence in the North East of India, 
Papumpare at AAR 30.2 with the lowest in Dibrugarh, also in the North East of India with AAR of 
4.9. 2 (Figure 3) 
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These epidemiological differences may well be underpinned by a difference in cancer genomics and 
biology, differences in prevalence of cancer risk factors, or both, and efforts to unravel these will be 
absolutely vital to effective cancer control and prevention efforts. (Box-1)  
 
Applications of cancer genomics  
 
Population Diversity and Cancer Genomics 
 
India is the sixth largest country in size and is the second most populous country in the world at 1.2 
billion. (http://www.censusindia.gov.in). The majority of the modern Indian population comprises a 
mix of  two large genetically divergent and heterogeneous population groups that mixed in ancient 
times (about 1200–3500 BC), known as Ancestral North Indians (ANI) or the Caucasoids and 
Ancestral South Indians (ASI) or the Australoids.23  Overall there are more than 4000 
anthropologically distinct groups and 22 languages with various dialects in this diverse nation. 24 
This diversity is enhanced by caste and religion based boundaries and consanguinity, making 
clusters of specific diseases and founder mutations a possibility.23  
 
This genetic diversity is represented in an extremely limited way in current bioinformatics 
databases, posing challenges for research and meaningful clinical interpretation. For instance the 
Exome Aggregation Consortium which seeks to aggregate and harmonize exome sequencing data 
has limited representation of population of Indian origin.25   An excellent resource is the Indian 
Genome Variation Consortium project which has studied polymorphisms in 900 genes from 55 
different population groups (http://www.igvdb.res.in/). This forms an important database for design 
of further studies of multifactorial as well as single gene disorders. 26 Another excellent advance is 
the TMC-SNPdb: an Indian germline variant database derived from whole exome sequences 
representing 114 309 unique germline variants-generated from whole exome data of 62 normal 
samples derived from cancer patients of Indian origin. 27 
 
Even with these advances, population level sequencing or genotyping data for India is quite limited 
at present, with only a few hundred whole genome datasets among various institutions, and some 
larger array-type studies to draw upon. The 100,000 Asian Genomes Project will give access to the 
largest amount of India Sequence data in future and is in planning stages. 28 A truly representative 
pan Indian genomic variant data resource across diverse ethnic groups is a key challenge to be 
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overcome if implementation of genomics to improve clinical care in India is to be a reality. 29 ( Box-
1)  
 
  
Cancer being a disease at a genome level, every patient has a unique profile, at both pathological 
and molecular levels. However, shared germline mutations are known to confer susceptibility risk. 
This has inspired the design of linkage analysis studies to identify regions of the genome shared 
across families carrying the same phenotype, most successful in the identification of the BRCA1 
and BRCA2 genes. 30 31 Such approaches however cannot explain the entire incidence, and the focus 
has since shifted to association studies of common variants, with potentially modest effect. These 
genome-wide association studies (GWAS) are based on more, albeit less informative, markers, 
shared further generations back than in linkage studies. This allows for the analysis of larger cohorts 
without the need to collect familial information and has led to hundreds of studies being performed 
across the world resulting in the association of thousands of genetic loci with numerous phenotypes. 
Famously genetic background could link up geographical information, especially across the 
numerous GWAS performed in Europe.32 This underlying structure of the data admirably reflects 
population diversity at a genetic level; conversely this also raises concerns about the validity of 
GWAS findings in populations distinct from the original region of discovery and undermines 
associations where cases and controls had different backgrounds.  
 
Carefully elucidating the effect of population diversity in India through well planned GWAS studies 
is likely to yield valuable fresh insights into disease aetiology and responses to drug therapy.  
Recently the first such study in an Indian population to examine a large number of GWAS-
identified breast cancer risk loci has been published. 33 Using such cohorts especially enriched for a 
given phenotype, may maximize the information and find valuable associations with key genes even 
with limited cohort size. 34 Furthermore, if appropriately recognized, limited population 
heterogeneity is an opportunity to increase the power of discovery. 35 Finally, the larger scale of 
analysis enables the creation of cohorts sharing predisposition beyond the molecular susceptibility, 
such as response to environmental factors. (Box -1) 
 
Studies comparing genotype-phenotype interactions are of particular interest in populations where it 
is possible to compare between Indian groups in India and Indian groups settled elsewhere, say the 
West.  For instance, the Punjab region in India has deep cultural, family links at multiple levels with 
the West Midlands region of the UK. The Indian Punjabi diaspora came to the UK in the 1950s and 
have settled in the major conurbations including Birmingham.36 Large scale parallel studies in 
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women’s cancer patients in Punjab and the Punjabi diaspora in the UK may offer the unique 
opportunity to compare and contrast genetic and environmental influences in cancer behavior in 
genetically related populations subject to very different environmental milieu and can provide 
insight into cancer prevention. (Box 1) Punjab state benefits from a robust population based registry 
covering both the urban area of Chandigarh UT as well as Sangrur, Mansa and SAS Nagar districts. 
(http://www.canceratlaspunjab.org/) Apart from known epidemiological risk factors driving cancer 
incidence such as visceral obesity, tobacco and alcohol consumption, increased pesticide use in 
agriculture and higher levels of heavy metal in water and food have been postulated as drivers 
specific to Punjab.37  
 
 
Familial cancer in women  
Approximately 10% of women with breast cancer, 20% with ovarian cancer and up to 9% with 
uterine cancer display inherited mutations in germline DNA as reported in studies performed in the 
West. 38-40 Importantly, these mutations are also identified in ‘unselected women’ with cancer that is 
those without a family history of cancer or early age of onset. 41The autosomal dominant disorders, 
hereditary breast and ovarian cancer (HBOC) with mutations in the BRCA 1 and 2 genes and Lynch 
syndrome (formerly referred to as hereditary nonpolyposis colorectal carcinoma, HNPCC) with 
mutations in the mismatch repair genes underlie the majority of this inherited susceptibility. Women 
with a BRCA1 mutation have a lifetime risk of ovarian cancer by age 70 years of up to 63% and of 
breast cancer by age 70 years of up to 85%. Risks of ovarian and breast cancers in women by age 
70 years among BRCA2 carriers are reported to be up to 27% and 84% respectively. 42 43 Mutations 
are in high prevalence genes BRCA 1 and 2, PALB2, TP53, PTEN, CDH1, STK11, genes with 
moderate prevalence CHEK2, BRIP1, RAD51, and ATM as well as in the Lynch syndrome family 
of genes MLH1, MSH2, MSH6, PMS2 and EPCAM.  Identifying families at risk and 
characterization of risk can enable evidence based large scale targeted prevention and screening 
efforts to reduce mortality from these cancers. Risk reducing interventions such as prophylactic 
mastectomy, bilateral salpingo- oophorectomy in in women with a familial risk of cancer in 
developed countries have robustly demonstrated reductions in cancer incidence and mortality.  44-46 
While population-based mammography screening is unlikely to be useful in India at present, 
targeted screening efforts using mammography in these ‘at risk’ populations, with careful age 
constraints  on publically available programs may prove cost effective and reduce mortality. 47  
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We also highlight a note of caution here – that screen-detected cancers may have a different 
genomic and phenotypic presentation than clinically detected cancers. Cancers that present 
clinically are more commonly biologically aggressive cancers, more commonly basal or triple-
negative tumours, which screen detected (clinically occult) cancers are more commonly ER+ more 
biologically favourable variants.  
 
In this context, it would be helpful to investigate the differences between screen detected cancers 
and clinically detected cancers in the South Asian populations who have migrated to high income 
countries. ( Box1)  Data on this is currently limited, as unfortunately, South Asian immigrants 
settled in the United Kingdom and North America have lower screening uptake rates for breast, 
cervical and colorectal cancers 48  
 
Furthermore, considerable diversity in mutation profiles by ethnicity exists in the BRCA 1 and 2 
genes.49 Whilst substantial information about the prevalence and spectrum of BRCA mutations 
exists in European and North American populations information is lacking in other populations, 
including the Indian population. Using data from Caucasian populations to interpret data from non –
Caucasian populations can be highly misleading and lead to misdiagnosis.50 In addition, the 
inherited risk of breast and ovarian cancer risks vary by type and location of BRCA1/2 mutations, 
making it vital to characterise the spectrum of mutations by ethnicity. 51 
 
Current data on the prevalence and nature of BRCA mutations and other inherited cancer 
predisposing genes in the Indian population is valuable but limited to single centre studies, 
relatively small sample sizes, restricted to selected women with strong family history of cancer, 
using older technologies e.g. Sanger sequencing. 52 53 More recently two pivotal studies using panel 
testing and Next generation sequencing have been published. 54 55 The first study screened 91 
patients with family history of Hereditary breast or ovarian cancer or early onset of cancer from 
Southern India, previously tested negative by an earlier PCR-dHPLC (PCR-denaturing high 
performance liquid chromatography)-based, by targeted resequencing of a multi-gene panel and 
reported a mutation rate of 26.4% (24/91). The second study identifies up to 36% prevalence of 
pathogenic mutations in breast and ovarian cancer susceptibility genes in women tested with a 
private provider, including some sporadic patients. 54 55   
 
There is an urgent unmet need for large scale studies recruiting unselected women with Breast, 
ovarian and uterine cancer from across the different regions of India, from both urban and rural 
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distributions, carefully annotated with clinical, pathological, survival data, tested with pan cancer 
panels using NGS to characterize the prevalence and spectrum of mutations and variants of 
uncertain significance in Indian women.  In order to tease apart intrinsic biological differences from 
environmental factors, and to assess the interplay of the two, it is essential that data should be also 
collected on epidemiological characteristics and environmental exposures to potential carcinogens. 
(Box1) 
 
 
Human Papilloma virus (HPV) infection and Cervical cancer 
 
As previously discussed, Cervical cancer incidence rates differs widely across regions in India. 
Furthermore, HPV variants differ in oncogenic potential, because of differences in biological, 
biochemical effects. 56 The oncogenicity of distinct HPV variants may also differ between 
geographical regions because of differences in the population related to the distribution of HLA 
alleles. 57 Efforts to understand the natural history of HPV infection and the development of cervical 
cancer across regions of varying incidence of cancer; establishing type and infection rates of HPV 
through population based cohort studies and characterization of India-wide HPV genome variants 
will be critical to the development of India specific low cost vaccines and HPV diagnostics ( Box 
1).  Recently complete genome sequences of HPV 16 isolates from lesions in Indian women have 
been published. 58 
 
Influence of environmental risk factors 
 
Genetic heterogeneity between endogamous groups within India is at least 3-fold higher than that 
observed between European populations, which is attributable to different waves of migration and 
admixture. Further, the genetic variants interact with the diverse environmental factors within India 
and exhibit such diverse effects across different geographic regions and ethnic groups. 
Wide variations in cancer types and incidence between various regions in India maybe due to 
genetic variations in a proportion of patients, however it is also highly likely that environmental 
factors, lifestyle and habits play a bigger role. 
 
For instance, significant variations in the cancer type and presentation are found in the Indian 
subcontinent compared to the rest of the world some of which can be related to specific differences 
in environmental exposure e.g. in case of oral cancer , which is the predominant cancer type in men 
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in India. Oral cancer predominantly presents as tongue cancer in the West, while in India it 
predominantly affects the gingivo-buccal region, comprising buccal mucosa, retro-molar trigone 
and lower gum. This might be related to the chewing betel-quid comprising betel leaf (Piper betle), 
areca nut (Areca catechu) and slaked lime (predominantly calcium hydroxide), with or without 
tobacco, is traditional and popular in India and is known to cause oral cancer. 59 Human papilloma 
virus (HPV) infection is also an established risk factor, with prevalence in oral cancer ranging 
between 20 and 50% across geographical regions. 60 
 
Ongoing efforts in cancer genomics in India 
 
A recent Global cancer genomics consortium conference at Mumbai showcased the vibrant cancer 
genomics research field in India, with progress in several cancers, including oral cancer, lung 
cancer, cervical cancer and gliomas.  61 The National Institute of Biomedical genomics, Kolkata 
(NIBMG) has had significant infrastructural funding from the Department of Biotechnology, Govt 
of India to address some of the questions key to Indian cancer.   
 
The International Cancer Genome Consortium (ICGC) has been launched to generate high 
resolution catalogues of genomic and other biological alterations in tumours of more than 50 
different cancer types/subtypes that have clinical and societal importance across the globe. Oral 
cancer occurs more frequently in Indian populations; nearly 73.4% of Head and neck cancer in 
India is from gingivobuccal origin as compared to 22% of cancer in the West and is associated with 
extensive tobacco and betel nut chewing practices. 18 In view of the high prevalence and existence 
of possible interacting environmental factors, India, a founder member of ICGC, is focusing on oral 
squamous cell cancer – gingivo-buccal – in the Indian component of the project. NIBMG, along 
with Advanced Centre for Treatment, Research and Education in Cancer ( ACTREC), Mumbai as 
the clinical partner, is spearheading the Indian initiative in ICGC which is funded by Department of 
Biotechnology, Govt. of India. The key objective of this initiative is to identify genomic, 
epigenomic and transcriptomic landscapes of alterations that drive OSCC-GB. NIBMG has 
developed substantial infrastructure and expertise in genomic analysis of cancer and is generating 
and analyzing genomic, epigenomic and transcriptomic data in the project. The OSCC-GB data in 
ICGC is available on http://dcc.icgc.org/projects/ORCA-IN. 62 63 In addition, NIBMG is engaged in 
studies on genomics, epigenomics and transcriptomics of oropharyngeal cancer and gastric cancer 
in specific populations in the North Eastern region of India (Meghalaya and Mizoram respectively), 
genomic studies on cervical, breast and pancreatic cancer as well as whole genome sequencing 
studies to catalogue the genomic variation of different populations of the Indian subcontinent.  
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Institutions actively engaged in capacity building in India for genomics include the National 
Institute of Biomedical genomics, Institute of Genomics and Integrative Biology, Council of 
Scientific & Industrial Research, India and others.  Indian research funders Department of 
Biotechnology, Indian Council of Medical Research have initiated Infrastructure Development at 
institutes for advanced Genomic Research and pharmacogenomics implementation across several 
sites in India. 64 A national Bioethics committee has established regulatory guidelines for Genomic 
medicine techniques, research activities and harmonization with international ethical guidelines.  
 
Capacity building for research in genomics in India 
 
Capacity building for research in genomics in India will require a multipronged approach, with the 
need to train scientists in next generation sequencing, bioinformatics and health care providers 
including clinicians, nurses and counsellors in engaging with informed consenting of patients, 
nuanced interpretation and communications of results.  Ongoing efforts such as the infrastructure to 
collect large scale prospective clinical, pathological, therapy and survival data such as the National 
cancer grid will also be vital to this effort.8 Patient – public engagement by researchers and 
effective advocacy through patient groups will be pivotal. All these efforts may be enhanced by 
public-private partnerships.  
 
India’s standing as a leader in Information technology, the large pool of graduates trained in the 
traditionally valued science disciplines and India’s demographic dividend may be fortuitous in 
creating the right conditions to create a genomic powerhouse. The Government of India has 
launched ambitious initiatives to improve online infrastructure and internet connectivity with 
‘Digital India’ and a commitment to making India the skills capital of the world, ‘Skills India’ 
which may facilitate the skilling up of graduates in the relevant disciplines. 65 66 The Government of 
India has also launched a massive project, called Aadhar, to provide a digital identity based on an 
individual's fingerprints and retina scans. As of 2016, the program had issued 12-digit identification 
numbers to 1.1 billion people. 67 These initiatives are pivotal in imagining a future where 
individuals can carry health data in conjunction with a digital identity.  
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Whilst advances in massively parallel sequencing have revolutionized our understanding of 
disease genomics and personalized medicine, it has also unleashed an enormous amount of data, 
both structured and unstructured, prompting experts and scientists to coin the term “BIG DATA”. 
These huge data sets have challenged the community to devise new sets of analytical and data 
access tools. It is important to highlight the lack of experience and expertise in bioinformatics while 
dealing with analysis of big data in India. There are currently very few islands of excellence where 
expertise exists to evaluate and meaningfully analyse big data from genomics research. Other areas 
of deficit include the lack of expertise in statistical genetics, systematic data management, data 
management of array data and a lack of basic computational facilities required to store and manage 
huge databases. Institutions such as NIBMG and ACTREC conduct capacity building workshops 
focusing on focused on cutting edge experimental and computational tools of 
contemporary genomics.  International collaborations with ongoing training efforts such as those 
established by Health Education England for UK health care system workers as part of the UK 
100,000 genome sequencing efforts may potentiate capacity building. 68 
 
Need for efficient research networks  
 
Integrated research systems that can prevent duplication of research efforts, optimize research 
reach, impact and output by creating clusters that can work synergistically and work well together. 
A provocative questions workshop between the US NCI and DBT, India identified key issues 
regarding cancer research in India, including the need for increased cancer research funding, and a 
focus on providing relevant human resource training and technology sharing platforms. Continued 
open debate between researchers, funders and policymakers will be essential to effectively 
strengthen the cancer research portfolio in India.69  
 
Clusters of research collaborations results in greater synergy, effective use of administrative costs. 
For instance, the AMPATH partnership has resulted in collaborators from > 19 universities and 
academic institutions in Africa, Europe, and North America working synergistically across Kenya, 
resulting in more than 275 publications in 17 years in over 90 active research projects securing 
more than $83.4M in research funding. (http://www.ampathkenya.org/) Indian clusters such as the 
Chandigarh Research and Innovation cluster (CRIKC), bringing together research active 
organizations across a wide range of expertise can facilitate effective research delivery. 
(http://crikc.puchd.ac.in/) Other models include innovative partnerships, such as the successful 
collaboration between the University of Cambridge, the National Centre for Biological Sciences 
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and Institute for Stem Cell Biology and Regenerative Medicine (inStem), Bangalore CBS resulting 
in the establishment of the multidisciplinary Centre for Chemical Biology and Therapeutics, 
Bangalore.  A landmark initiative, the Indian National Cancer Grid now links more than 85 major 
cancer centers to build a platform that will enable development and dissemination of Indian 
guidelines, uniformity in training in training in cancer care and establish Pan India cancer research 
networks. 8 This development is a key step to enabling the delivery of clinical and translational 
research at scale.  
 
Increased research capacity and training, protected time for clinical researchers; enhanced 
collaborative funding programs and development of infrastructures across a range of domains 
including clinical trials and tissue banking have been identified as cancer research priorities in 
India. 22 Research capacity building for manpower to staff biobanks, animal house laboratories, 
genomics and bioinformatics will also add to the skills base development in India as championed by 
the Skills Development agenda (http://www.makeinindia.com/home) from the Government of India.   
 
Initiatives from funders such as the Wellcome trust – Department of Biotechnology India alliance 
fellowships for clinical and non-clinical researchers will contribute significantly to capacity 
building for research. (http://www.wellcomedbt.org/). The Newton fund was launched in 2014 and 
commits to £ 75 million pounds each year of research spending with global partners. This is set to 
increase to £150 million by 2021. (http://www.newtonfund.ac.uk/). A significant funding stream for 
UK-India relevant research is the Newton-Bhabha funding stream, delivered jointly between the 
Research Councils UK and the Department of Biotechnology India.   
 
Public Health Implications  
 
Cancer accounts for 12% of premature deaths in Low and middle income countries ( LMIC’s)  with 
7.6% of Disability adjusted Life years (DALY) lost due to cancer.70 The WHO has also set an 
ambitious target of reduction of death from non-communicable disease including cancer by 25% by 
2025 in its recent global monitoring framework. 71 
 
There are a range of socio-economic and socio-cultural factors that can also play a role in the 
variation in site-specific incidence and survival that is observed globally, and by region and 
race/ethnicity within countries such as India. 72 73 Specifically, barriers to early detection in India 
 
 
15 
stem from factors including low cancer literacy, stigma, fear, health care access and cost of care.74  
A recent review found low literacy for breast cancer awareness in Indian women, including nursing 
professionals, whose knowledge of risk factors was not aligned with the importance/strength of a 
risk factor.75  Cancer mortality patterns reveal the importance of socio-economic determinants 
including geographical location such as the Northeast or living in rural areas for women or 
infectious-related cancers, low education and religion. 74 Individual- and societal-level social 
barriers for breast cancer in Indian women include cancer stigma, fear, fatalism and financial 
constraint. 76 Global evidence shows the importance of health-systems constraints for women’s 
cancers related to development of health services, availability of health insurance, distance to 
cancer services as well as gender equity and human development. 77 Thus, sociocultural barriers to 
cancer control are key challenges in India. 78  
 
 
Public health measures to tackle cancer control include the Package of essential NCD interventions 
championed by the World Health Organisation (WHO) for primary health care addressing cancer, 
diabetes, heart disease and stroke, chronic respiratory disease; a conceptual framework for 
strengthening equity and efficiency of primary health care in low-resource settings; it identifies core 
technologies, medicines and risk prediction tools; discusses protocols required for implementation 
of a set of essential NCD interventions; develops technical and operational outline for integration of 
essential NCD interventions into primary care and for evaluation of impact. 
(http://www.who.int/cardiovascular_diseases/publications/pen2010/en/) 
 
 
In addition, there is a substantial knowledge deficit on cultural attitudes to genetic testing amongst 
patients and caregivers as well as the awareness of inherited cancer risk in Indian women. Shyness, 
fear of cancer, stigma, financial constraints are some of the barriers to early detection of cancer. 79 
Qualitative studies to assess the type and magnitude of the various barriers will be important; to 
ensure that insight gained by cutting edge genomic technologies translates into real benefit in 
screening, prevention for family members at risk. Studies that promote cancer literacy and 
understanding social and cultural barriers to cancer prevention will also be important. 80 (Box-1) 
Thus, whilst genomics based research may enable a better understanding of ethnic variations in 
cancer patients in India and enable India specific cost effective interventions, it is only one factor in 
a much broader framework of cancer control and not likely to be a universal panacea.  
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Genomics and improving Outcomes from womens cancers   
How might a better understanding of Genomics improve outcomes from women’s cancer in India 
given such prevalent sociocultural barriers? Population based screening methods for India may not 
be affordable or cost effective, given equally competing demands for universal education, sanitation 
amongst others. However understanding India specific differences through genomics may enable 
the identification of women at high risk of development of cancer where targeted screening may be 
cost effective. We need to urgently identify Indian specific genetic/epigenetic biomarkers related to 
intermediates of breast cancer like mammographic density. These may have potential to be used as 
biomarkers for early detection at screening stage. Equally a greater understanding of the 
oncogenicity of HPV variants in Indian woman will help the development of low cost vaccines for 
cervix cancer.  Treatment regimens developed using evidence generated from trials performed on 
Caucasian women may not be applicable or as effective in a population with such distinct 
phenotypical differences. Developing evidence based India specific paradigms of screening and 
management are therefore essential to improving outcomes.  
 
Conclusions  
We envisage that genomics technologies harnessed to understand India specific differences in the 
presentation, epidemiology and clinical behaviour of women’s cancer may  lead to the development 
of appropriate cost effective, targeted screening and prevention for women at risk of development 
of Breast and ovarian cancer, new strategies for prevention in Cervix cancer as well as effective 
cancer treatment paradigms. 
Strong multidisciplinary research teams comprising expertise in clinical studies, genomics, 
bioinformatics, modeling, qualitative research and public health will need to work collaboratively to 
harness the immense potential offered by novel next generation sequencing technologies. This will 
ensure that the benefits from these technologies are harnessed in an evidence based and cost 
effective way to improve women’s health and alleviate cancer burden in India.  
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